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tivecommons.org/licenses/by-nc-Summary Systemic sclerosis is a multisystem autoimmune rheumatic disorder characterized
by fibrosis in the skin and internal organs but rarely with hepatic or brain involvement. Revers-
ible posterior leukoencephalopathy syndrome is characterized by a unique pattern of brain va-
sogenic edema in the setting of neurotoxicity predominantly in the parietal and occipital
regions. We report a case of systemic sclerosis associated with probable autoimmune hepatitis
that progressed rapidly to reversible posterior leukoencephalopathy syndrome with loss of
vision, seizures, and coagulopathy. Brain computed tomography showed faint low density in
the bilateral occipital lobes and posterior parietal lobes with edematous change. Fortunately,
the patient’s clinical condition considerably improved 2 days following the initiation of 100 mg
intravenous hydrocortisone infusion.
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112 W.-H. Chang et al.Introduction
Systemic sclerosis (SS) is a systemic disorder characterized
by inflammation, fibrosis and degeneration of the skin,
blood vessels, and internal organs [1]. Nearly all patients
with SS have peripheral vascular involvement with Raynaud
syndrome, and >80% experience gastrointestinal function
change such as dysphagia. SS rarely has hepatic involve-
ment especially autoimmune hepatitis. Rodrigues et al [2]
reported a patient with diffuse SS who was diagnosed
with autoimmune hepatitis and who had an excellent
response to immunosuppressive drugs.
Reversible posterior leukoencephalopathy syndrome
(RPLS), or posterior reversible encephalopathy syndrome, is
characterizedbyauniquepatternofbrainvasogenicedema in
the setting of neurotoxicity predominantly in the parietal and
occipital regions [3]. It may develop in patients with immu-
nosuppressed conditions and various rheumatologic diseases.Figure 1 (A) The patient had Raynaud’s phenomenon and digita
angiopancreatography image shows gallstones (white arrow) with i
show a hypodense area in the occipital lobe, which is a characte
arrow).Fugate et al [4] noticed that a substantial proportion of pa-
tients with RPLS had underlying autoimmune disorders. They
described focal regions of symmetric hemispheric edema on
computed tomography (CT) or magnetic resonance images
[5]. However, the etiology of presentation was unknown;
underlying vasculitis, cerebral autoregulation disorder, and
hypertensive encephalopathy were considered [6]. RPLS is
reversible and is characterized by headaches, decreased
alertness, altered mental status, seizures, and visual loss.
We present a patient with underlying SS who developed
acute liver injury, seizure, and visual loss, and whose con-
dition considerably improved following hydrocortisone
intravenous infusion.
Case report
A 71-year-old woman experienced nausea, vomiting, and
intermittent epigastric pain for 10 days accompanied byl pitting scar (white arrow). (B) The magnetic resonance chol-
ntact biliary duct. (C) The brain computed tomography images
ristic of posterior reversible encephalopathy syndrome (white
Figure 2 Level of total bilirubin (mg/dL) and international
normalized ratio over the course of treatment with endoscopic
retrograde cholangiopancreatography and steroid
intervention.
Autoimmune hepatitis and SS complicated by RPLS 113general malaise, poor appetite, and tea-colored urine. She
was previously diagnosed with early progressive SS and
hypertension at outpatient clinics and was maintained with
4 mg methylprednisolone and 8 mg candesartan daily. She
had not taken any new drugs or herbal medicine or
consumed alcohol prior to presentation. The patient was
afebrile when she visited the emergency department. Her
initial vital signs were a body temperature of 36.3C, pulse
rate of 63 beats/min, and respiratory rate of 18 breaths/
min. She had icteric sclera and yellowish skin. She pre-
sented with Raynaud phenomenon affecting the fingers,
with a digital pitting scar (Figure 1A) and sclerodactyly. The
initial biochemistry evaluation revealed the following:
total/direct bilirubin, 9.9/6.9 mg/dL (normal range
0.3e1.2/0.1e0.5 mg/dL); aspartate/alanine transaminase,
412/282 IU/L (normal range 15e41/14e41 IU/L); alkaline
phosphatase, 854 IU/L (normal range 38e126 IU/L);
gamma-glutamyl transpeptidase, 649 IU/L (normal range
7e50 IU/L); blood urea nitrogen, 43 mg/dL (normal range
8e20 mg/dL); creatinine, 3.7 mg/dL (normal range
0.4e1.2 mg/dL); amylase, 285 mg/dL (normal range
28e100 mg/dL); lipase, 82 mg/dL (normal range 22e51 mg/
dL); white blood cells, 10,000/mL (normal range
4000e10,000/mL); platelets, 237,000/mL (normal range
140,000e450,000/mL); lactate dehydrogenase, 283 IU/L
(normal range 93e192 IU/L); and antinuclear factor 640Xþ
(normal range < 40þ). The following serology tests were
negative: viral hepatitis A, B, and C, herpes simplex virus 1,
cytomegalovirus, EpsteineBarr virus, rheumatic factor,
immunoglobulin G, C3, C4, anti-ds-DNA, antimitochondrial
antibody, and antismooth muscle antibody. Abdominal ul-
trasonography showed chronic liver parenchymal disease
and gallbladder stones, but normal diameter of the com-
mon bile duct. Further magnetic resonance chol-
angiopancreatography showed a normal common bile duct
(Figure 1B).
After 4 days of supportive care, the patient’s jaundice
worsened (total bilirubin, 13.2 mg/dL) with coagulopathy
(prothrombin time, 13.9 seconds). At this time, the pa-
tient experienced sudden altered mental status with
seizure, vision loss, and elevated blood pressure (180/
77 mmHg). She was diagnosed with acute liver failure and
hypertensive crisis. Brain CT showed faint low density in
the bilateral occipital lobes and posterior parietal lobes
with edematous change that was diagnosed as RPLS
(Figure 1C).
An aggressive control of blood pressure was attempted
with nifedipine plus 5 mg amlodipine/80 mg valsartan QD.
Liver biopsy was not possible because of coagulopathy;
however, a 100-mg intravenous hydrocortisone injection
was administered every 12 hours because of concern of
impending autoimmune acute liver failure. Fortunately, her
clinical condition, including consciousness level, vision loss,
and kidney and liver function, considerably improved after
2 days (Figure 2). Following 2 weeks of 100 mg intravenous
hydrocortisone therapy, we tapered the steroid dose to
10 mg oral prednisolone twice daily. The patient became
asymptomatic with normal liver function, and her status
was maintained with 4 mg/d methylprednisolone. After
follow-up for 9 months, her liver function test results were
within the normal range.Discussion
Reports describe an association between autoimmune
hepatitis and SS; therefore, elevation of liver enzyme levels
should be monitored [2]. Our patient had acute hepatitis
with severe jaundice, coagulopathy, and acute conscious
change due to RPLS, a condition that mimicked sudden
onset acute liver failure, but not hepatic encephalopathy
because she had no preexisting liver disease, and the
abdominal CT scan showed no liver cirrhosis. The most
frequent symptoms of RPLS include headache, seizures,
and visual changes.
The etiology of RPLS is thought to be failure of cerebral
autoregulation in severe hypertension along with possible
additive injury secondary to uremia, cytotoxic drug use,
and microthrombi formation [7]. It may be associated with
certain autoimmune disorders, including autoimmune hep-
atitis and rheumatic diseases under immunosuppressant
treatment, and with chemotherapy treatment [6]. Howev-
er, the mechanism by which immunosuppressive therapy
might cause RPLS is unclear. Hypertensive encephalopathy
is a feature in the majority of RPLS patients; treatments for
hypertension are thought to resolve RPLS [3,8].
It is difficult initially to identify the causes of acute liver
injury. We excluded viral hepatitis, alcohol- or drug-related
hepatitis, and congestive heart failure-related hepatitis by
initial evaluation. Using the revised Original Scoring System
of the International Autoimmune Hepatitis Group, the pa-
tient’s posttreatment aggregate score was 17, which
strongly suggested autoimmune hepatitis [9]. Steroid
treatment is controversial in acute liver failure. However,
this patient had a good response to steroid treatment.
Although connective tissue-related autoimmune hepatitis
has rarely been described, it was thought to be a liver
manifestation associated with SS [10].
In conclusion, we suggest that the cause of RPLS might
be the use of immunosuppressants because of SS and
autoimmune hepatitis. The reversible nature of RPLS makes
114 W.-H. Chang et al.the diagnosis important. Adequate treatment of hyperten-
sion and autoimmune hepatitis is necessary. Further studies
are required establish treatment guidelines. It is worth-
while for young residents to keep this in mind when doing
emergent treatment.
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